A Phase I, Open-label, Single-arm Study to Determine the Single and Multiple Dose Pharmacokinetics of 10mg ZD4054 Administered Once Daily in Male, Elderly Chinese Patients With Advanced Solid Malignancies.
Latest Information Update: 26 Apr 2013
At a glance
- Drugs Zibotentan (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 18 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 18 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.